The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc)

February 2011

The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc).

Atypicals are used to treat conditions such as psychosis or schizophrenia. Latuda is now the TENTH oral atypical antipsychotic.

More money is spent on antipsychotics than any other class.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Pediatrics Just 1 or 2 doses of some medications can kill a young child
Antidepressants confusion about which bupropion to dispense
Neurology & Pain Butrans (BYOO-trans), a new once-a-week C-III buprenorphine patch for chronic pain
Hemorrhoids which products to use for hemorrhoidal symptoms
Antipsychotics The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc)
Pregnancy the differences in prenatal vitamins
Pediatrics Kapvay, the new clonidine extended-release for attention deficit hyperactivity disorder (ADHD) in children
Osteoporosis Atelvia (uh-TEL-vee-uh), increases the chance for mishaps with osteoporosis meds
Injectables the first INJECTABLE acetaminophen, Ofirmev (uh-FIRM-ev)
Medication Errors preventing mishaps with Catapres-TTS (clonidine) transdermal patches
New Drugs new drugs approved in 2010
Acetaminophen Prescription combo pain meds (Lorcet, Tylox, etc) will be limited to only 325 mg of acetaminophen per tab or cap
Diabetes Meds Cycloset, a new form of bromocriptine for type 2 diabetes